+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response



Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response



European Journal of Immunology 16(12): 1479-1487



Regulation of the expression of influenza A/PR/8/34 hemagglutinin (HA) by the vaccinia virus promoters PF (early), P7.5 (early and late) and PL11 (late) has been demonstrated using HA-vaccinia recombinant viruses VV-PR8-HA3, VV-PR8-HA6 and VV-PR8-HA, respectively. Levels of HA on the surface of VV-PR8-HA3 (PF)-infected cells were lower than with either VV-PR8-HA6 (P7.5) or VV-PR8-HA8 (PL11). Expression of HA under the control of the late promoter PL11 was inhibited in the absence of DNA replication. All three recombinant viruses stimulated a specific antibody response in mice which was dependent on the presence of infectious virus. Recognition of HA by cytotoxic T lymphocytes (CTL) was assessed by the ability of the viruses to stimulate naive precursors in vivo, to restimulate primed CTL in vitro and by target cell recognition. HA expressed under the control of either of the promoters with early function (PF or P7.5) was recognized by CTL when VV-PR8-HA3 or VV-PR8-HA6 were used to prime or restimulate splenocytes or to infect target cells. On the other hand, HA expressed by VV-PR8-HA8 (PL11) failed to prime for a CTL response in naive CBA/H mice, was ineffective at restimulation of primed splenocytes and failed to produce target cells for recognition by specific CTL. However, in BALB/c mice VV-PR8-HA8 did prime for a specific CTL response. These studies show that HA synthesized early in infection was recognized by both B and T cells while HA expressed after DNA replication was not generally recognized by T cells. The implications of the observations with the late promoter with respect to the use of late promoters in potential vaccinia virus-based vaccines are considered.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 006586807

Download citation: RISBibTeXText

PMID: 3493144

DOI: 10.1002/eji.1830161203


Related references

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune system. Chanock, R M , Et Al (Ed ) Vaccines, 87 Modern Approaches to New Vaccines: Prevention Of Aids And Other Viral, Bacterial, And Parasitic Diseases; Conference, Cold Spring Harbor, New York, Usa, 1986 Xxiii+461p Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, Usa Illus Paper 72-76, 1987

Recombinant vaccinia virus expressing the pr 8 influenza hemagglutinin overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. Clinical Research 40(2): 195A, 1992

The roles of influenza virus hemagglutinin and nucleoprotein in protection analysis using vaccinia virus recombinants. Scandinavian Journal of Immunology 25(1): 21-28, 1987

Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. Journal of Infectious Diseases 168(2): 352-357, 1993

Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microbial Pathogenesis 1(5): 443-452, 1986

Protection of MHC class I-deficient mice against influenza A infection by vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Journal of Cellular Biochemistry Suppl. 0(17 Part D): 65, 1993

B2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Journal of Immunology 150: 84-93, 1993

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21(17-18): 2097-2106, 2003

Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Journal of Immunology 150(12): 5484-5493, 1993

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17(7-8): 887-892, 1999

Method of inducing an immune response using vaccinia virus recombinants. Official Gazette of the United States Patent & Trademark Office Patents 1264(1), 2002

Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus. Virology 280(2): 211-220, 2001